Quintrio
Home

PHARMACEUTICAL PREPARATIONS

SIGA Technologies Inc.

SIGA

SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.

Last trade $2.75
Day change -$0.105 (-3.68%)
Day range $2.75 – $2.89
Volume 466,737
Market cap $205M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$204.79M
Price / earnings
298.44×
Price / book
1.25×
Price / sales
3.91×
EV / sales
1.69×
EV / EBITDA
-12.94×

Profitability

Earnings per share
$0.01
Return on assets
0.4%
Return on equity
0.42%
Dividend yield
21.19%

Liquidity and leverage

Debt / equity
0×
Current ratio
24.57×
Quick ratio
18.4×
Cash ratio
17.27×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.57M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SIGA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.32M$41M$6.24M$3.79M$2.62M$81.12M$7.04M$81.47M
Cost of revenue$575.66K$17.56M$2.94M$2.99M$1M$25.55M$157.74K$14.13M
Gross profit$741.31K$23.44M$3.3M$804.47K$1.62M$55.57M$6.88M$67.34M
Selling, general and administrative$4.62M$5.15M$4.67M$5.26M$4.79M$5.49M$5.68M$6.91M
Research and development$2.64M$4.39M$3.95M$5.04M$7.05M$4.4M$3.46M$3.34M
Total operating expenses$7.26M$9.54M$8.62M$10.3M$11.84M$9.89M$9.14M$10.25M
Operating income-$6.52M$13.91M-$5.32M-$9.5M-$10.22M$45.68M-$2.26M$57.09M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$5.48M$14.85M-$4.04M-$7.96M-$8.36M$47.27M-$570.42K$58.58M
Income taxes-$2.59M$2.39M-$589.43K-$2.53M-$1.99M$11.79M-$162.19K$12.82M
Net income-$2.89M$12.46M-$3.45M-$5.43M-$6.37M$35.48M-$408.22K$45.76M
Net income attributable to common shareholders-$2.89M$12.46M-$3.45M-$5.43M-$6.37M$35.48M-$408.22K$45.76M
EBITDA-$6.37M$14.06M-$5.17M-$9.35M-$10.08M$45.82M-$2.12M$57.22M
Basic earnings per share-$0.04$0.17-$0.05-$0.08-$0.09$0.50-$0.01$0.64
Diluted earnings per share-$0.04$0.17-$0.05-$0.07-$0.09$0.49-$0.01$0.63

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

SIGA (SIGA) Q3 2026 Earnings Call Transcript

SIGA Technologies reported Q3 2026 results with $1.3M in quarterly revenue and a $2.9M net loss, though improved from prior year. The company completed its BARDA 19C contract obligations and secured a new Canadian Department of National Defence contract valued up to $15M over five years with $9M in firm commitments. However, timing for a new U.S. government procurement contract remains uncertain, and the Post-Exposure Prophylaxis supplemental NDA filing has been delayed to 2028. SIGA maintains a strong balance sheet with $116.4M in cash and zero debt.

The Motley Fool

SIGA (SIGA) Q1 2026 Earnings Call Transcript

SIGA Technologies reported Q1 2026 results with minimal product deliveries ($6M total revenue, $3M net loss) but highlighted strong forward momentum including a $13M Asia-Pacific oral TPOXX order expected in Q2, a new exclusive distribution agreement with Hikma for the Middle East and North Africa region, and ongoing development of pediatric and post-exposure prophylaxis formulations. The company maintains a strong balance sheet with $146M in cash and no debt, and paid a $0.60 special dividend per share.

Benzinga

SIGA Declares Special Cash Dividend of $0.60 Per Share

SIGA Technologies announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. The dividend amount matches the special dividend declared in April 2025. CEO Diem Nguyen stated the announcement reflects the company's strong balance sheet and commitment to shareholder value while executing its strategy in global health and infectious disease prevention.

GlobeNewswire Inc.

ACTG Announces Publication of STOMP Results in the New England Journal of Medicine

A major clinical trial (STOMP) published in the New England Journal of Medicine found that tecovirimat, an FDA-approved smallpox drug, did not improve mpox resolution in outpatient adults with clade II mpox. The randomized, placebo-controlled study of 412 participants showed 79% clinical resolution in the tecovirimat group versus 81% in the placebo group by day 29, with no significant differences in pain reduction or lesion healing.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Apr 7, 2026$0.60Apr 23, 2026special
Apr 29, 2025$0.60May 15, 2025special
Mar 25, 2024$0.60Apr 11, 2024special
May 15, 2023$0.45Jun 1, 2023special
May 16, 2022$0.45Jun 2, 2022special

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.